Correlation Between Neurocrine Biosciences and Merck

Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Merck at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Merck into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurocrine Biosciences and Merck Company, you can compare the effects of market volatilities on Neurocrine Biosciences and Merck and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Merck. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Merck.

Diversification Opportunities for Neurocrine Biosciences and Merck

-0.26

Correlation Coefficient

Neurocrine Biosciences  Merck

Very good diversification

The 3 months correlation between Neurocrine and Merck is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Merck Company in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Merck Company and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Merck. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Merck Company has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Merck go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Merck

Given the investment horizon of 90 days Neurocrine Biosciences is expected to under-perform the Merck. In addition to that, Neurocrine Biosciences is 1.73 times more volatile than Merck Company. It trades about -0.12 of its total potential returns per unit of risk. Merck Company is currently generating about 0.01 per unit of volatility. If you would invest  13,099  in Merck Company on January 30, 2024 and sell it today you would earn a total of  21.00  from holding Merck Company or generate 0.16% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	95.45%
Values	Daily Returns

Neurocrine Biosciences  vs.  Merck Company

Neurocrine Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, Neurocrine Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Merck Company

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Merck Company are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Merck may actually be approaching a critical reversion point that can send shares even higher in May 2024.

Pair Trading with Neurocrine Biosciences and Merck

The main advantage of trading using opposite Neurocrine Biosciences and Merck positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Merck can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Merck will offset losses from the drop in Merck's long position.

The idea behind Neurocrine Biosciences and Merck Company pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.